人神经干细胞治疗小儿脑瘫的临床安全性研究  

Study on clinical safety of human neural stem cells in treatment of cerebral palsy in children

作　　者：闫冬梅[1] 汪洪流[1] 周培杰[1] 单玲[1] 

机构地区：[1]江苏省连云港市妇幼保健院,222006

出　　处：《中国妇幼保健》2014年第22期3595-3597,共3页Maternal and Child Health Care of China

基　　金：江苏省连云港市十二五科教兴卫创新型人才科技支撑项目〔SH1009〕

摘　　要：目的:探讨人神经干细胞临床治疗小儿脑瘫的安全性。方法:对28例脑瘫患儿采用立体定向移植的方法,将培养好的、符合需要的人神经干细胞移植入患儿额叶、内囊前肢或脑室旁等脑实质处。比较手术治疗前后患儿的血常规常用指标、肝肾功能、出凝血时间以及体温、血压、精神状态等一般情况有无差异。结果:脑瘫患儿治疗前后红、白细胞总数、血红蛋白、血小板、总蛋白、尿素氮、肌酐以及出凝血时间、体温、血压等比较,差异均无统计学意义(P>0.05)。结论:神经干细胞治疗小儿脑瘫的临床应用是安全可行的。Objective： To explore the safety of human neural stem cells in treatment of cerebral palsy in children. Methods： Stereotactic transplantation method was used for 28 children with cerebral palsy, the neural stem cells after culture and meeting the requirements were transplanted into the brain parenchyma （frontal lobe, anterior limb of internal capsule or beside encephalocoele） ; the commonly used blood routine examination indicators, liver function and kidney function, coagulation time, body temperature, blood pressure and mental state before and after treatment were compared. Results： There was no statistically significant difference in total amounts of red blood cells and white blood cells, hemoglobin, blood platelet, total protein, urea nitrogen, creatinine, coagulation time, body temperature and blood pressure in children with cerebral palsy between before and after treatment （P 〉 0. 05） . Conclusion ： The clinical application of neural stem cells in treatment of children with cerebral palsy is safe and feasible.

关 键 词：人神经干细胞 脑性瘫痪 移植 安全性 

分 类 号：R748[医药卫生—神经病学与精神病学]